Sanofi Terminates SAR448272 STAT6 Degrader Program, Ending Nurix Milestone Stream
NRIX sits 89% above its 52-week low of $11.67.
Summary
Sanofi discontinued the Phase 1 trial of SAR448272 and terminated the program, so Nurix will receive none of the future milestones or royalties tied to that STAT6 degrader. Other licensed Sanofi programs remain eligible, but only if Sanofi chooses to advance them.
Key Events · M&A and Partnerships · NRIX
-
Sanofi Kills SAR448272 Program
Collaboration partner Sanofi notified Nurix on November 3, 2026 that it will discontinue the Phase 1 first-in-human trial of SAR448272, an oral STAT6 degrader, and terminate the program.
-
Future Milestone Stream Eliminated
Nurix does not expect to receive any of the future development, regulatory and commercial milestone payments or royalties it was eligible for under the Sanofi Collaboration with respect to SAR448272.
-
Other Sanofi Programs Still Eligible
Nurix remains eligible for milestones and royalties on its other previously announced licensed programs under the Sanofi Collaboration, but only if Sanofi exercises its discretion to develop them further into clinical candidates.
-
Cash Position Absorbs the Setback
The termination lands two weeks after Nurix reported a $549.8M Q3 profit on $673.1M revenue and $1.1B in cash funding operations into 2029, so the loss is pipeline value rather than a liquidity problem.
Analysis · NRIX · Life Sciences
Sanofi is walking away from SAR448272, the oral STAT6 degrader it licensed from Nurix, after the Phase 1 first-in-human trial. Every future development, regulatory and commercial milestone and royalty tied to that program is gone — a partnered pipeline asset disappears, and with it a slice of the out-year revenue the collaboration was supposed to generate. The balance sheet softens the blow: the company just reported $1.1B in cash funding operations into 2029, so this is a pipeline setback rather than a financing crisis. Nurix says it stays eligible for milestones and royalties on its other licensed Sanofi programs, but those depend on Sanofi's discretion to advance them — the same discretion it just exercised by pulling the plug here.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRIX was trading at $22.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $11.67 to $28.23. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.